RENAL INTERACTION OF ATRIAL NATRIURETIC PEPTIDE WITH ANGIOTENSIN II: GLOMERULAR AND TUBULAR EFFECTS
- 1 February 1989
- journal article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 16 (2) , 97-107
- https://doi.org/10.1111/j.1440-1681.1989.tb01533.x
Abstract
1. The possible interactions between the renal effects of atrial natriuretic peptide (ANP) and angiotensin II (AII) were studied in normal sodium-replete human subjects. Recent investigations have suggested that ANP inhibits the pressor and volume-retaining effects of activation of the renin-angiotensin system. Thus, ANP may attenuate the effects of AII on renal haemodynamics or tubular transport. 2. ANP (0.1 micrograms/kg per min, 60 min) was intravenously infused into eight normal human subjects with and without pretreatment with enalapril (20 mg, per oral), an inhibitor of the converting enzyme, and during infusion of AII (10 mg/kg per min). 3. ANP infusion alone caused increases in the urine volume (from 96 +/- 23 to 229 +/- 44 mL/h, P less than 0.05) and urinary sodium excretion (from 11.5 +/- 1.6 to 20.9 +/- 4.2 mEq/h, P less than 0.05). These changes were accompanied by an increase in the glomerular filtration rate (from 127 +/- 9 to 158 +/- 9 mL/min, P less than 0.05). ANP infusion after enalapril administration lowered the mean blood pressure (from 76 +/- 2 to 71 +/- 3 mmHg, P less than 0.05) to a level similar to that observed during ANP infusion alone (from 84 +/- 2 to 74 +/- 2 mmHg, P less than 0.01), but did not result in a significant diuresis (from 139 +/- 23 to 174 +/- 51 mL/h) or natriuresis (from 19.7 +/- 2.5 to 14.3 +/- 3.4 mEq/h, P less than 0.05). This combined treatment with a converting enzyme inhibitor and ANP reduced both the glomerular filtration rate (160 +/- 9 to 141 +/- 10 mL/min) and the renal plasma flow (from 775 +/- 49 to 570 +/- 45 mL/min, P less than 0.01). 4. The antinatriuretic effects of exogenous AII were reversed by superimposed ANP infusion (urinary sodium excretion: from 4.8 +/- 1.0 to 24.3 +/- 5.2 mEq/h, P less than 0.01). Under these conditions, the glomerular filtration rate increased (from 114 +/- 6 to 156 +/- 7 mL/min, P less than 0.05) to levels similar to those observed with ANP infusion alone. In addition the increased tubular sodium reabsorption induced by AII was inhibited by concomitant ANP infusion (fractional proximal tubular sodium reabsorption: from 90.7 +/- 3.5 to 80.3 +/- 16.6%, P less than 0.05, fractional post-proximal tubular sodium reabsorption: from 91.5 +/- 9.8 to 87.6 +/- 8.8%, P less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)Keywords
This publication has 29 references indexed in Scilit:
- Enalapril attenuates natriuresis of atrial natriuretic factor in humans.Hypertension, 1988
- Site of the action of a synthetic atrial natriuretic peptide evaluated in humansKidney International, 1987
- Effects of atrial natriuretic peptide (ANP) during converting enzyme inhibitionActa Physiologica Scandinavica, 1987
- Prolonged administration of human atrial natriuretic peptide in healthy men. Reduced aldosteronotropic effect of angiotensin II.Hypertension, 1986
- Atriopeptin: A Cardiac Hormone Intimately Involved in Fluid, Electrolyte, and Blood-Pressure HomeostasisNew England Journal of Medicine, 1986
- Blood levels and renal effects of atrial natriuretic peptide in normal man.Journal of Clinical Investigation, 1986
- Administration of atrial natriuretic factor inhibits sodium-coupled transport in proximal tubules.Journal of Clinical Investigation, 1985
- Natriuretic Effect and Changes in Renal Haemodynamics Induced by Enalapril in Essential HypertensionDrugs, 1985
- A very sensitive direct radioimmunoassay system for plasma angiotensin II and its clinical application in various hypertensive diseases.Japanese Circulation Journal, 1984
- Increased Glomerular Filtration Rate after Converting-Enzyme Inhibition in Essential HypertensionNew England Journal of Medicine, 1979